Hongxi Wu | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Mrs. Hongxi Wu | Cancer Biology | Best Researcher Award 

Professor, at China Pharmaceutical University, China.

Dr. Hongxi Wu is a distinguished Research Fellow, Associate Professor, and Graduate Supervisor at the Department of Pharmacology, School of Pharmacy, China Pharmaceutical University. With extensive experience in molecular pharmacology and precision oncology, his research focuses on understanding gene regulatory mechanisms in cancer progression and drug resistance. Dr. Wu has made significant contributions to prostate and liver cancer treatment by identifying novel biomarkers and therapeutic targets. As a leading investigator, he has secured multiple national-level grants and published extensively in high-impact journals. His work bridges fundamental research with clinical applications, aiming to enhance cancer therapy outcomes through innovative drug discovery.

Professional Profile

Scopus

ORCID

Education 🎓

Dr. Wu pursued his academic journey at China Pharmaceutical University. He earned his Bachelor’s degree in Pharmacoeconomics (2007-2011), followed by a Master’s degree in Pharmacology (2011-2014). He continued his Ph.D. research in Pharmacology (2014-2017), investigating molecular mechanisms underlying cancer progression and drug resistance. Dr. Wu then advanced his expertise as a Postdoctoral Research Scientist (2017-2021), further exploring targeted therapies for castration-resistant prostate cancer and hepatocellular carcinoma. His educational background laid a strong foundation for his innovative research in cancer pharmacology.

Research Experience 👩‍🎓

Dr. Wu’s research delves into the molecular mechanisms of gene regulation in cancer, focusing on castration-resistant prostate cancer and liver cancer. He has identified key biomarkers, including AR and ARv7 variants, IRF8, CDK9, and CLKs, which influence prognosis and drug efficacy. His work extends to developing novel combination therapies, such as 2-Methoxyestradiol with Erlotinib and sorafenib with enzalutamide, to enhance treatment effectiveness. Additionally, he investigates innovative anticancer compounds targeting AR, CDK9, and Clk1/2 through chemical biology strategies, aiming to overcome drug resistance in precision oncology.

Research Interests 🎡

Dr. Wu’s primary research interests lie in cancer pharmacology, precision medicine, and targeted therapies. He focuses on understanding tumor progression, metastasis, and drug resistance mechanisms. His work aims to identify novel therapeutic targets and develop personalized treatment strategies for aggressive cancers. Dr. Wu is particularly interested in androgen receptor biology, immune response modulation, and the role of gene expression in chemotherapy resistance. His research integrates molecular biology, pharmacogenomics, and chemical biology to develop innovative cancer treatments.

Awards & Honors 🏆

Dr. Wu has received several prestigious awards recognizing his contributions to cancer research. In 2023, he was honored with the SHIMADZU Young Scholar’s Award for his groundbreaking work in pharmacology. He has also secured multiple research grants, including funding from the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, and the China Postdoctoral Science Foundation. His outstanding research achievements have earned him national and international recognition, further solidifying his reputation as a leading cancer pharmacologist.

Top Noted Publications 📚

  • Wu H, et al. (2024). Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer.

  • Wu H, et al. (2023). Flavonoid-based CDK9 degraders for prostate cancer treatment.

  • Wu H, et al. (2022). Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances anti-PD1 therapy.

  • Wu H, et al. (2022). A novel AR inhibitor induces protein degradation to overcome enzalutamide resistance in prostate cancer.

  • Wu H, et al. (2020). Loss of IRF8-AR feedback promotes prostate cancer growth and enzalutamide resistance.

Conclusion

Dr. Hongxi Wu is an exceptionally strong candidate for the Best Researcher Award, given his outstanding contributions to oncology pharmacology, impactful publications, and success in securing competitive research grants. While further international collaborations, industry engagement, and leadership in global research networks could further enhance his profile, his achievements in cancer research, particularly in overcoming drug resistance, make him a highly deserving nominee.

Mahnoosh Mokhtarinejad | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Mrs . Mahnoosh Mokhtarinejad | Cancer Biology | Best Researcher Award 

Laboratory Expert , Faculty of Pharmacy and Pharmaceutical of sciences, Hormozgan University of Medical sciences, Iran .

Mahnoosh Mokhtarinejad is a researcher in genetics, with expertise in cancer biology, gene expression, and bioinformatics. Based in Iran, she holds advanced degrees in Human Genetics and Cellular and Molecular Biology. She currently works as a laboratory expert and technician at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Iran. Her research focuses on the molecular aspects of cancer, particularly head and neck squamous cell carcinoma (HNSCC).

Profile

Scopus

Education

🎓 Mahnoosh earned her Master’s degree in Human Genetics from Tehran University of Medical Science (2016-2018), where her thesis explored the expression of specific lncRNAs and mRNAs in HNSCC. Prior to this, she completed a Bachelor’s degree in Cellular and Molecular Biology-Genetics from Shahid Chamran University of Ahvaz (2011-2015), with coursework covering biochemistry, genetics, and oncology.

Experience

🧪 Mahnoosh has worked as a Laboratory Expert and Technician at Hormozgan University of Medical Sciences since 2021, where she conducts research on gene expression in cancer cells. She also serves as a teaching assistant, guiding pharmacy students through laboratory experiments. She previously worked as a Medical Sales Representative for Niksan Salamat Behbood Company in 2020.

Research Interests

🔬 Mahnoosh’s research interests revolve around cancer biology, gene expression regulation, epigenetics, pharmacogenetics, and bioinformatics. She is particularly focused on the molecular mechanisms underlying cancers like HNSCC, exploring the role of long non-coding RNAs (lncRNAs) and tumor suppressor genes.

Awards

🏆 Mahnoosh has been actively engaged in academic and professional circles, contributing to her field through participation in congresses such as the IRHRC Annual Meeting on Reproductive and Infertility Updates.

Publications

📚 2024
Mokhtarinejad, M., Pirhoushiaran, M., Heidarzadehpilehrood, R., Hesami, S., Azmoudeh-Ardalan, F., Shakoori Farahani, A. Upregulated long non-coding RNAs TMPO-AS1, DDX11-AS1, and POLE gene expression predict poor prognosis in head and neck squamous cell carcinoma (HNSCC). Gene Reports, cited by 6 articles.

📚 2020
Mehrabi, S., Pirhoushiaran, M., Eshaghkhani, Y., Teimourzadeh Baboli, A., Mahmoudi, A., Zarifian Yeganeh, R., Abdollahzadeh, R., Sadeghi Rad, H., Mokhtarinejad, M., Shakoori Farahani, A. Molecular Analysis of EGFR and PIK3CA Genetic Mutations in Iranian Patients with Head and Neck Squamous Cell Carcinoma. International Journal of Pharmaceutical and Phytopharmacological Research, cited by 12 articles.

📚 2023
Jamil, M., Mohammadi-Bardbori, A., Safa, O., Nikpoor, A.R., Bakhtari, A., Mokhtarinejad, M., Naybandi Zadeh, S., Shadboorestan, A., Omidi, M. Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis. Drug Research, cited by 4 articles.

Conclusion

Mahnoosh Mokhtarinejad is a strong candidate for the Best Researcher Award, with a rich background in cancer genetics, particularly focusing on molecular aspects of head and neck squamous cell carcinoma. Her publications in reputable journals, technical expertise, and role as a laboratory expert reflect her dedication to scientific advancement. However, expanding her leadership in large-scale research projects and enhancing her international exposure could further elevate her profile for this award. Overall, her work in cancer genetics holds significant promise and aligns well with the criteria for recognition in research excellence.